Journal of Biomedical Science Impact Factor

The first useful signal is that the journal's citation performance is now well inside the upper tier of broad biomedical publishing. This is not a vanity jump built on heavy self-citation either. The JIF without self-cites is 12.0, almost identical to the reported JIF, which is a clean trust signal.

The second useful signal is that the journal has become stronger without becoming narrow. Authors often assume a broad biomedical title will be more permissive if the science is competent. The metrics suggest the opposite: the journal is broad in scope but still selective about whether the manuscript really advances a meaningful biomedical problem through molecular or mechanistic evidence.

The JCI of 1.54 supports that read. It shows the journal performs clearly above the field-normalized baseline rather than only inside one local citation pocket.

The JCR row above is the authoritative impact factor on this page. The Scopus-based series below is useful only for direction: it shows whether the journal's broad biomedical citation demand is strengthening or softening around the official JIF.

Directionally, the open citation signal is up from 8.54 in 2023 to 11.86 in 2024. That is a material year-over-year rise after a softer 2023. The broader picture is even more useful: the journal has climbed far above its mid-2010s level and held onto that gain.

That usually means the market has repriced the journal. Authors who still think of it as a moderate secondary option are likely using an outdated mental model.

The common mistake is to read 14.5 and assume the journal wants any respectable biomedical manuscript.

That is not how the scope is framed. The official aims emphasize fundamental and molecular aspects of basic medical sciences, with a specific focus on molecular studies of biomedical problems and molecular mechanisms.

In practice, the journal tends to reward papers where:

• the biomedical problem matters beyond one niche

• the mechanistic layer actually carries the claim

• the manuscript travels across adjacent biomedical readerships

• the medical relevance is shown in the evidence, not mostly declared in the discussion

That means the metric tells you the journal has reach. It does not tell you that a narrow or descriptive manuscript belongs there.

For manuscripts targeting Journal of Biomedical Science, the repeating issue is not obvious weakness. It is overestimation of breadth.

We see authors assume that because the journal is broad and open access, the editorial bar will be forgiving. Editors actually screen for a broader readership case and a stronger mechanism than many manuscripts have on first submission.

For manuscripts targeting Journal of Biomedical Science, four failure patterns recur.

The manuscript is technically strong but too local. It works for insiders, but the broader biomedical consequence is still hard to see.

The mechanism is thinner than the headline. Strong phenotypes, correlations, or pathway claims still fail if the molecular closure is not strong enough.

The medical relevance is rhetorical. The framing sounds biomedical, but the figures themselves do not yet carry that weight.

The first read undersells the problem. Editors actually have to see the biomedical problem and mechanistic consequence quickly, or the paper feels smaller than it is.

If that sounds like the draft, a Journal of Biomedical Science submission readiness check is usually more useful than another round of sentence-level polishing.

The impact factor does not tell you whether the paper has enough mechanism, enough cross-field readability, or enough biomedical consequence for this journal. It also does not tell you whether the manuscript belongs in a disease-specific or specialty venue instead.

That is where most mismatches happen. The metric places the journal. It does not solve the breadth problem for the author.